Specific IgG antibody responses may be used to monitor leprosy treatment efficacy and as recurrence prognostic markers

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 30, Issue 10, 2011, Pages 1257-1265

  Duthie, M S ^a,b   Hay, M N ^b   Rada, E M ^c   Convit, J ^c   Ito, L ^d   Oyafuso, L K M ^d   Manini, M I P ^e   Goulart, I M B ^f   Lobato, J ^f   Goulart, L R ^f   Carter, D ^b   Reed, S G ^a  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^b Protein Advances Inc   (United States)

^c INSTITUTO DE BIOMEDICINA   (Venezuela)

^d FACULDADE DE MEDICINA DO ABC   (Brazil)

^e Secretaria de Estado da Saude de Sao Paulo   (Brazil)

^f FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; PHENOLIC GLYCOLIPID I; RECOMBINANT PROTEIN;

ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; ANTIGEN DETECTION; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; BORDERLINE LEPROSY; BRAZIL; CLINICAL ASSESSMENT TOOL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFICACY; DRUG RESPONSE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LEPROMATOUS LEPROSY; LEPROSY; MULTIBACILLARY LEPROSY; MULTIDRUG RESISTANCE; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; RELAPSE; TUBERCULOID LEPROSY; VENEZUELA;

ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BRAZIL; DRUG MONITORING; HUMANS; IMMUNOGLOBULIN G; LEPROSY; LONGITUDINAL STUDIES; RECOMBINANT PROTEINS; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME; VENEZUELA;

EID: 80054756386     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-011-1221-2     Document Type: Article

References (35)

1. DM Scollard 2004 Classification of leprosy: a full color spectrum, or black and white? Int J Lepr Other Mycobact Dis 72 166 168 15301586 10.1489/1544-581X(2004)072<0166:COLAFC>2.0.CO;2
2. DS Ridley WH Jopling 1966 Classification of leprosy according to immunity. A five-group system Int J Lepr Other Mycobact Dis 34 255 273 5950347 1:STN:280:DyaF2s%2FhtVWluw%3D%3D
3. World Health Organization (WHO) 2007 Global leprosy situation, 2007 Wkly Epidemiol Rec 82 225 232
4. A Meima JH Richardus JD Habbema 2004 Trends in leprosy case detection worldwide since 1985 Lepr Rev 75 19 33 15072123
5. B Ji P Jamet S Sow EG Perani I Traore JH Grosset 1997 High relapse rate among lepromatous leprosy patients treated with rifampin plus ofloxacin daily for 4 weeks Antimicrob Agents Chemother 41 1953 1956 9303392 1:CAS:528:DyaK2sXlvFOgtbY%3D
6. E Cambau P Bonnafous E Perani W Sougakoff B Ji V Jarlier 2002 Molecular detection of rifampin and ofloxacin resistance for patients who experience relapse of multibacillary leprosy Clin Infect Dis 34 39 45 11731943 10.1086/324623 1:CAS:528:DC%2BD38XmvFSgsA%3D%3D
7. S Maeda M Matsuoka N Nakata M Kai Y Maeda K Hashimoto, et al. 2001 Multidrug resistant Mycobacterium leprae from patients with leprosy Antimicrob Agents Chemother 45 3635 3639 11709358 10.1128/AAC.45.12.3635-3639.2001 1:CAS:528:DC%2BD3MXovVOksbg%3D
8. M Matsuoka Y Kashiwabara Z Liangfen M Goto S Kitajima 2003 A second case of multidrug-resistant Mycobacterium leprae isolated from a Japanese patient with relapsed lepromatous leprosy Int J Lepr Other Mycobact Dis 71 240 243 14608820 10.1489/1544-581X(2003)71<240:ASCOMM>2.0.CO;2
9. M Matsuoka Y Kashiwabara M Namisato 2000 A Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin and sparfloxacin Int J Lepr Other Mycobact Dis 68 452 455 11332288 1:CAS:528:DC%2BD3MXjs1ejurY%3D
10. ST Reece G Ireton R Mohamath J Guderian W Goto R Gelber, et al. 2006 ML0405 and ML2331 are antigens of Mycobacterium leprae with potential for diagnosis of leprosy Clin Vaccine Immunol 13 333 340 16522774 10.1128/CVI.13.3.333-340.2006 1:CAS:528:DC%2BD28XjsVGqu7c%3D
11. MS Duthie W Goto GC Ireton ST Reece LP Cardoso CM Martelli, et al. 2007 Use of protein antigens for early serological diagnosis of leprosy Clin Vaccine Immunol 14 1400 1408 17898185 10.1128/CVI.00299-07 1:CAS:528:DC%2BD2sXhtl2nurnN
12. MS Duthie GC Ireton GV Kanaujia W Goto H Liang A Bhatia, et al. 2008 Selection of antigens and development of prototype tests for point-of-care leprosy diagnosis Clin Vaccine Immunol 15 1590 1597 18716007 10.1128/CVI.00168-08 1:CAS:528:DC%2BD1cXhtlChtb3L
13. MS Duthie MN Hay CZ Morales L Carter R Mohamath L Ito, et al. 2010 Rational design and evaluation of a multiepitope chimeric fusion protein with the potential for leprosy diagnosis Clin Vaccine Immunol 17 298 303 20016045 10.1128/CVI.00400-09 1:CAS:528:DC%2BC3cXitlCis7s%3D
14. J Rudeeaneksin S Srisungngam P Sawanpanyalert T Sittiwakin S Likanonsakul S Pasadorn, et al. 2008 LightCycler real-time PCR for rapid detection and quantitation of Mycobacterium leprae in skin specimens FEMS Immunol Med Microbiol 54 263 270 18783434 10.1111/j.1574-695X.2008.00472.x 1:CAS:528:DC%2BD1cXhtlagurnE
15. J Lobato DA Silva TW Mineo JD Amaral GR Segundo JM Costa-Cruz, et al. 2006 Detection of immunoglobulin G antibodies to Neospora caninum in humans: high seropositivity rates in patients who are infected by human immunodeficiency virus or have neurological disorders Clin Vaccine Immunol 13 84 89 16426004 10.1128/CVI.13.1.84-89.2006 1:CAS:528:DC%2BD28XmvF2ntA%3D%3D
16. E Rada M Ulrich N Aranzazu V Rodriguez M Centeno I Gonzalez, et al. 1997 A follow-up study of multibacillary Hansen's disease patients treated with multidrug therapy (MDT) or MDT + immunotherapy (IMT) Int J Lepr Other Mycobact Dis 65 320 327 9401484 1:STN:280:DyaK1c%2FmsVymuw%3D%3D
17. SN Cho RV Cellona LG Villahermosa TT Fajardo Jr MV Balagon RM Abalos, et al. 2001 Detection of phenolic glycolipid I of Mycobacterium leprae in sera from leprosy patients before and after start of multidrug therapy Clin Diagn Lab Immunol 8 138 142 11139208 1:CAS:528:DC%2BD3MXmtVenuw%3D%3D
18. EA Silva A Iyer S Ura JR Lauris B Naafs PK Das, et al. 2007 Utility of measuring serum levels of anti-PGL-I antibody, neopterin and C-reactive protein in monitoring leprosy patients during multi-drug treatment and reactions Trop Med Int Health 12 1450 1458 18076551 10.1111/j.1365-3156.2007.01951.x 1:CAS:528:DC%2BD1cXhtlSiu7w%3D
19. DN Lockwood AJ Reid 2001 The diagnosis of leprosy is delayed in the United Kingdom QJM 94 207 212 11294963 10.1093/qjmed/94.4.207 1:STN:280:DC%2BD3M3oslKjug%3D%3D
20. C Flower D Gaskin S Marquez 2007 A case of recurrent rash and leg numbness mimicking systemic rheumatic disease: the occurrence of leprosy in a nonendemic area J Clin Rheumatol 13 143 145 17551381 10.1097/RHU. 0b013e318064e7a0
21. H Anderson B Stryjewska BL Boyanton MR Schwartz 2007 Hansen disease in the United States in the 21st century: a review of the literature Arch Pathol Lab Med 131 982 986 17550332
22. GA Ellard VK Pannikar K Jesudasan M Christian 1988 Clofazimine and dapsone compliance in leprosy Lepr Rev 59 205 213 3200085 1:STN:280: DyaL1M%2FntVWjsQ%3D%3D
23. ER Honrado V Tallo AC Balis GP Chan SN Cho 2008 Noncompliance with the World Health Organization-multidrug therapy among leprosy patients in Cebu, Philippines: its causes and implications on the leprosy control program Dermatol Clin 26 221 229 18346553 10.1016/j.det.2007.11.007 1:CAS:528: DC%2BD1cXkvVymtLw%3D
24. RA Miller D Gorder JP Harnisch 1987 Antibodies to phenolic glycolipid-I during long-term therapy: serial measurements in individual patients Int J Lepr Other Mycobact Dis 55 633 636 3323367 1:STN:280:DyaL1c7hslSntA%3D%3D
25. PW Roche WJ Britton SS Failbus KD Neupane WJ Theuvenet 1993 Serological monitoring of the response to chemotherapy in leprosy patients Int J Lepr Other Mycobact Dis 61 35 43 8326179 1:STN:280:DyaK3szhsF2hsQ%3D%3D
26. S Chanteau JL Cartel P Celerier R Plichart S Desforges J Roux 1989 PGL-I antigen and antibody detection in leprosy patients: evolution under chemotherapy Int J Lepr Other Mycobact Dis 57 735 743 2681456 1:STN:280: DyaK3c%2FjvVyjsw%3D%3D
27. GJ Ebenezer G Norman GA Joseph S Daniel CK Job 2002 Drug resistant-Mycobacterium leprae-results of mouse footpad studies from a laboratory in south India Indian J Lepr 74 301 312 12624978 1:STN:280: DC%2BD3s7ht1Gjtg%3D%3D
28. DL Williams TP Gillis 2004 Molecular detection of drug resistance in Mycobacterium leprae Lepr Rev 75 118 130 15282962
29. M Matsuoka T Budiawan KS Aye K Kyaw EV Tan ED Cruz, et al. 2007 The frequency of drug resistance mutations in Mycobacterium leprae isolates in untreated and relapsed leprosy patients from Myanmar, Indonesia and the Philippines Lepr Rev 78 343 352 18309708
30. PW Roche KD Neupane SS Failbus CR Butlin 2000 Dapsone drug resistance in the MDT era Int J Lepr Other Mycobact Dis 68 323 325 11221097 1:STN:280:DC%2BD3M7ktlaqtw%3D%3D
31. JH Grosset CC Guelpa-Lauras P Bobin G Brucker JL Cartel M Constant-Desportes, et al. 1989 Study of 39 documented relapses of multibacillary leprosy after treatment with rifampin Int J Lepr Other Mycobact Dis 57 607 614 2674301 1:STN:280:DyaL1MzotFGhtQ%3D%3D
32. RH Gelber LP Murray P Siu M Tsang TH Rea 1994 Efficacy of minocycline in single dose and at 100 mg twice daily for lepromatous leprosy Int J Lepr Other Mycobact Dis 62 568 573 7868955 1:STN:280:DyaK2M7ntlCquw%3D%3D
33. B Ji J Grosset 2000 Combination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy Lepr Rev 71 Suppl S81 S87 11201894
34. B Ji EG Perani C Petinom L N'Deli JH Grosset 1994 Clinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepromatous leprosy Antimicrob Agents Chemother 38 662 667 8031029 1:STN:280:DyaK2czgsVWjtA%3D%3D
35. MF Balagon RV Cellona RM Abalos RH Gelber PR Saunderson 2010 The efficacy of a four-week, ofloxacin-containing regimen compared with standard WHO-MDT in PB leprosy Lepr Rev 81 27 33 20496567